Testosterone therapy and venous thromboembolism risk in men with and without hypogonadism
JAMA Nov 18, 2019
Walker RF, Zakai NA, MacLehose RF, et al. - In men with and without evidence of hypogonadism, researchers ascertained if short-term testosterone therapy exposure was correlated with increased short-term risk of venous thromboembolism (VTE). They observed an association between the use of testosterone therapy in the 6-month case period and an increased risk of VTE among men with and without hypogonadism in this case-crossover study comparing 6-month testosterone use for 39,622 men who had a VTE with testosterone use 6-12 months before the VTE. Such findings suggest that when prescribing testosterone therapy, caution should be used.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data